Pulmatrix Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases
The company utilizes its proprietary technology platform to create new treatments that target and modulate the underlying mechanisms of respiratory conditions, including chronic obstructive pulmonary disease (COPD) and asthma. Pulmatrix aims to improve the lives of patients through the development of novel inhaled therapeutics that enhance drug delivery and optimize treatment outcomes. With a commitment to advancing respiratory health, Pulmatrix is dedicated to bringing transformative solutions from the laboratory to the patients who need them.
Gainers Spero Therapeutics (NASDAQSPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.
Pulmatrix (NASDAQPULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.
During Friday's trading, 54 companies set new 52-week lows.
Things to Consider About Today's 52-Week Lows:
The largest company by market cap to hit a new 52-week...
Gainers
KAR Auction Services, Inc. (NYSEKAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2...
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...
Gainers
Cyren Ltd. (NASDAQCYRN) rose 54.6% to $7.48 in pre-market trading after gaining around 119% on Thursday. The company recently announced a $12 million private placement...
